论文部分内容阅读
目的:比较国产和进口硝苯地平控释片治疗高血压的药物经济学评价,提供最佳用药方案。方法:采用前瞻性随机对照研究,对国产和进口硝苯地平控释片治疗高血压进行药物经济学分析。结果:研究国产和进口硝苯地平控释片治疗高血压的产生单位效果所需的成本分别为431.8和507.2。结果证明两组临床疗效即降压效果无显著性差异。最小成本法比较,如果应用国产品其期望有效治疗成本平均每例可以节省约7000～8000元。两组成本-效果比有显著差异。结论:与进口硝苯地平比较,国产硝苯地平治疗原发性高血压仍不失为一个较佳的治疗方案。
OBJECTIVE: To compare the pharmacoeconomic evaluation of domestic and imported controlled release nifedipine tablets in treating hypertension and to provide the best medication regimen. Methods: A prospective randomized controlled study on domestic and imported controlled release tablets of nifedipine for the treatment of hypertension drug-economics analysis. RESULTS: The cost of studying the effects of home-made and imported controlled-release tablets of nifedipine on hypertension was 431.8 and 507.2, respectively. The results show that the clinical efficacy of the two groups that no significant difference in antihypertensive effect. Compared with the minimum cost method, an average of 7,000 to 8,000 yuan can be saved in each case if the expected cost of the applied product is expected to be on an average basis. There is a significant difference between the two cost-effectiveness ratios. Conclusion: Compared with the imported nifedipine, domestic nifedipine treatment of essential hypertension is still a better treatment.